Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 270 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Herpes Simplex Virus Infection Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 22, 2026, 1:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

NCT00002310
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response to Shingles Vaccination

NCT02624375
View directory record Official record
Conditions
Shingles
Interventions
Zoster Vaccine Live
Drug
Lead sponsor
University of Washington
Other
Eligibility
70 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

NCT02690207
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
8,687 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
37
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 22, 2026, 1:07 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
View directory record Official record
Conditions
Genital Herpes, HSV-2 Infection
Interventions
GEN-003, Matrix-M2, 0.9% normal saline
Biological · Other
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

NCT00224471
View directory record Official record
Conditions
Herpes Simplex
Interventions
GSK208141 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
671 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
9
States / cities
Mesa, Arizona • Fountain Valley, California • Golden, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ Vaccine (IN001), Placebo, Shingrix
Biological
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Industry
Eligibility
50 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional

The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood

NCT00001115
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Palo Alto, California • Torrance, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 22, 2026, 1:07 PM EDT
Not listed No phase listed Observational

Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia

NCT01166295
View directory record Official record
Conditions
Neuralgia, Herpes Zoster
Interventions
Not listed
Lead sponsor
Analgesic Solutions
Industry
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

NCT01331161
View directory record Official record
Conditions
Shingles
Interventions
ZOSTAVAX
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years to 79 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

NCT05513625
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, ESO and pritelivir
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 22, 2026, 1:07 PM EDT
Completed No phase listed Observational Results available

Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

NCT01878383
View directory record Official record
Conditions
Herpes Simplex Virus
Interventions
Genexpert assay
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
12,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 22, 2026, 1:07 PM EDT
Not listed No phase listed Observational

Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity

NCT05429346
View directory record Official record
Conditions
Genital Herpes Simplex, Maternal Morbidity, Racial Disparities
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
339,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

Effectiveness of TheraNeem Lip Therapy for Herpes Simplex Labialis

NCT00985335
View directory record Official record
Conditions
Herpes Simplex
Interventions
Neem Based External Application Cream
Other
Lead sponsor
Southern California University of Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

NCT01017185
View directory record Official record
Conditions
Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
Interventions
HF10
Drug
Lead sponsor
Takara Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
The Bronx, New York • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Withdrawn Phase 2 Interventional

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

NCT00506610
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
T-62
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Bradenton, Florida • Naples, Florida • New Port Richey, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional

An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

NCT00002021
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 1:07 PM EDT
Withdrawn Not applicable Interventional

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

NCT00682721
View directory record Official record
Conditions
Bacterial Vaginosis, Herpes Simplex Virus Type II
Interventions
Placebo, Valacyclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 22, 2026, 1:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

NCT02715752
View directory record Official record
Conditions
Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection, Cytomegalovirus Infections
Interventions
Gene-Eden-VIR/Novirin
Dietary Supplement
Lead sponsor
The Center for the Biology of Chronic Disease
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Valley Cottage, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Sep 22, 2026, 1:07 PM EDT